Phase 2 N=39 Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
Arthralgia · Breast Cancer
Primary: Absolute Change in Brief Pain Inventory (BPI) Worst Pain From Baseline to Week 15 — -2.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,504 Consumer Perceptions of Cannabidiol (CBD) Health Claims
Perceptions
Primary: Perceived Claim Scores — 2.96; 2.81; 2.71; 2.03 score on a scale
Phase 2 N=6 CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)
Radiculopathy
Primary: Change in Opioid Analgesic Plasma Levels — 10.86; -11.4 ng/mL
Phase 2 N=18 Cannabidiol Treatment in Patients With Early Psychosis
Schizophrenia · Schizoaffective Disorder
Primary: Positive and Negative Syndrome Scale (PANSS) Over Time — 81.3; 84.0; 78.3; 75.3 score on a scale — p=0.08
N/A N=26 Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
Metabolism · Liver Function · Pharmacokinetics
Primary: Pharmacokinetic Time to Maximum Concentration- (Tmax) for Different Formulations of CBD — 116.3; 35.4; 51.8; 129.5 minutes
Phase 2 N=50 Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
Smoking, Marijuana
Primary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm
Phase 2 N=64 CBD for Dental Pain
Odontalgia · Toothache
Primary: Intra-group VAS Pain Intensity and Maximum Pain Relief — 63; 69; 63; 21 score on a scale
Phase 2 N=40 Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
Phase 2 N=18 Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
Pain
Primary: Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test — 9.7; 2.2; 2.1; 1.2 Seconds
Phase 4 N=4 Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV
Chronic Inflammation
Primary: Number of Differentially Expressed Genes — 8.3 Differentially expressed genes
N/A N=38 Cannabidiol and Emotional Stimuli
Drug Addiction
Primary: Positivity Ratings of Social Images — 1.96; 1.68; 1.86; 1.93 score on a scale
Phase 2 N=57 The Effect of Cannabidiol in Learning and Memory of Adults
Memory
Primary: Sum of Trials (I-V) — 49.09; 47.17 score on a scale
Phase 2 N=27 Effects of Cannabidiol in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)
Phase 2 N=30 Cannabidiol as a Treatment for AUD Comorbid With PTSD
Alcohol Use Disorder · Post Traumatic Stress Disorder
Primary: Number of Drinks Per Day — 4.4885; 5.3623 drinks/day
Phase 3 N=100 The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
Pain, Postoperative
Primary: Pain Visual Analog Scale (VAS) Score — 4.4; 5.7 score on a scale
Phase 2 N=31 Enhancing Medication-based Analgesia in Humans- STUDY 2
Pain · Cannabis · Opioid Use
Primary: Peak Cold Pressor Tolerance — 118.6; 130.8; 161.1; 163.2 minutes — p=0.195
Phase 2 N=10 Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC) — 2.67; 0.83; -0.33; -0.17 units on…
Phase 2 N=42 Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue (30 Minutes), and From Test Day 1 Through Test Day 4 (1 Week)) - Via the Visual Analog Scale for…
Phase 2 N=3 Oral Cannabidiol for Opioid Withdrawal
Opioid Withdrawal · Opioid Craving · Opioid Use Disorder
Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events
Phase 2 N=125 Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
Insomnia
Primary: Percentage of Time Spent in the Combination of Slow Wave Sleep (SWS) and Rapid Eye Movement (REM) Sleep — 43.0; 41.8 Percentage of total sleep time — p=0.0350
Phase 2 N=36 Cannabidiol in Youth Alcohol Use Disorder
Alcohol Use Disorder
Primary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33
N/A N=361 Anxiety, Inflammation, Stress, and Cannabinoids
Anxiety · Anxiety Disorders · Anxiety Generalized
Primary: Change in Anxiety: Depression Anxiety Stress Scale (DASS21). — 9.38; 10.1; 10.5; 9.85 units on a scale
Phase 1 N=241 Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol · Drug Induced Liver Injury · Drug Interaction
Primary: Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper…
Phase 2 N=34 Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury
Muscle Injury · Recovery · Pain Relief
Primary: Self-report Ratings of Muscle Soreness — 0.0; 0.0 score on a scale
Phase 4 N=37 Cannabidiol for Bilateral Total Knee Arthroplasty
Pain, Postoperative · Opioid Use · Knee Osteoarthritis
Primary: Cumulative Opioid Usage in First 72 Hours Postoperatively — 209.0; 144.0; 203.2 Morphine Milligram Equivalents (MME)
Phase 2 N=41 Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Phase 2 N=15 Sublingual Cannabidiol for Anxiety
Anxiety
Primary: Change From Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI) — 20.97; 22.50; 21.00; 6.88 Score — p=<0.001
Early Phase 1 N=7 Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine
Addiction
Primary: Agitation Calmness Evaluation Scale (ACES) — 4; 4; 4; 4.07 score on a scale